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Abstract 31 
Anti-cancer drug Sunitinib is linked to adverse cardiovascular events, which have shown to 32 
involve mitogen activated kinase kinase 7 (MKK7) pathway. Sunitinib-induced cardiotoxicity 33 
in 3, 12 and 24 months old male Sprague-Dawley rats and MKK7 expression and activation 34 
was investigated using the Langendorff perfused heart model followed by Western blot 35 
analysis. Cardiac function and infarct size were measured during/after 125 minutes of 36 
Sunitinib treatment. Left ventricular cardiac samples were analysed by qRT-PCR for 37 
expression of MKK7 mRNA and cardiac injury associated microRNAs. Infarct size was 38 
increased in all Sunitinib treated age groups. Haemodynamic alterations were observed 39 
following Sunitinib administration. Left ventricular developed pressure (LVDP) was 40 
decreased in all age groups, while heart rate (HR) was decreased in 3 and 12 months groups. 41 
Sunitinib treatment decreased the expression of miR-27a in all age groups, while miR-133a 42 
and miR-133b levels were increased in 3 months and decreased in 24 months groups. MKK7 43 
mRNA and p-MKK7 levels were decreased in the 3 months group after Sunitinib treatment. 44 
MKK7 mRNA level was increased in 24 months group and p-MKK7 levels were increased in 45 
12 months group following Sunitinib treatment. This study highlights the importance and 46 
impact of ageing and anti-cancer therapy-induced cardiotoxicity. 47 
Keywords:  48 
Cardiac aging; Anti-cancer therapy; Sunitinib-induced cardiotoxicity; mitogen activated 49 
kinase kinase 7; cardiotoxicity microRNAs.  50 
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1. Introduction 51 
Life expectancy has increased substantially due to a combination of medical advances and 52 
improved quality of life. With the continuously growing elderly population, the number of 53 
elderly patients with cancer unfortunately increases. The median age at diagnosis of cancer is 54 
65 years, and the rate of cancer diagnosis increases with age in both males and females 55 
(Miller et al. 2016). Due to ageing of the population and the cardiotoxic nature of cancer 56 
treatment, there is an increasing number of elderly patients with cancer and comorbid 57 
cardiovascular diseases. It is therefore vital to unravel the pathways linked to developing 58 
cardiovascular diseases during anti-cancer treatment in elderly cancer patients to stratify the 59 
anti-cancer treatment at the time of cancer diagnosis. 60 
 61 
Ageing of the heart involves progressive deteriorations in its structure and function and is the 62 
leading risk factor for cardiovascular morbidity and mortality. Older people are significantly 63 
more likely to develop cardiovascular diseases (Lakatta 2003), such as left ventricular 64 
hypertrophy, diastolic dysfunction, valve degeneration, increased cardiac fibrosis, and 65 
decreased maximal exercise capacity (Dai et al. 2012). Furthermore, cardiac ageing is 66 
strongly associated with the development of heart failure (Ho et al. 1993). Needless to say, 67 
ageing of the heart causes it to become extremely vulnerable to external stress, such as 68 
cardiotoxic anti-cancer therapy.   69 
 70 
The tyrosine kinase inhibitor Sunitinib is used in the treatment of renal cell carcinoma, 71 
gastro-intestinal stromal tumour and pancreatic nero-endocrine tumour (Le Tourneau et al. 72 
2007). Sunitinib inhibits tyrosine kinases by competitively binding to the ATP-binding site 73 
domain of various receptor tyrosine kinases, notably: vascular endothelial growth factor 1-3 74 
and platelet derived growth factor-α and -β (O'Farrell et al. 2003). Binding to the ATP-75 
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binding domain causes the inhibition of dysregulated or over expressed tyrosine kinases 76 
involved in the regulation of angiogenesis cell proliferation and cell survival (Mendel et al. 77 
2003). Unfortunately, Sunitinib is associated with severe cardiotoxic adverse effects due to 78 
the broad molecular targets and lack of kinase selectivity of this tyrosine kinase inhibitor. 79 
Sunitinib-induced cardiotoxicity causes adverse effects in cardiomyocytes, which can lead to 80 
cardiac ischaemia and produce arrhythmias (Cohen et al. 2011). Also, left ventricular 81 
hypertrophy, hypertension and heart failure development have been reported in response to 82 
Sunitinib treatment (Ewer et al. 2014; Gupta and Maitland 2011).  Sunitinib-induced 83 
cardiotoxicity develops in approximately 2.7 % of the overall population (mean age 65 years) 84 
(Khakoo et al. 2008), while the overall incident of congestive heart failure has been reported 85 
to be 4.1 % (Richards et al. 2011). In the long-term follow-up study by Brunello et al. 86 
Sunitinib-induced cardiotoxicity in the elderly (≥ 70 years old) was recorded to be 13.3 %. 87 
The study followed 68 metastatic renal cell carcinoma patients treated with Sunitinib, out of 88 
which 9 developed cardiac events including asymptomatic decrease in LVEF, acute 89 
myocardial infarction, and congestive heart failure (Brunello et al. 2013). The rate of adverse 90 
cardiac event in the elderly treated with Sunitinib is increased dramatically in the study by 91 
Brunello et al. compared to the overall population, however it should be noted that the 92 
metastatic renal cell carcinoma patients in the study by Brunello et al. had a high prevalence 93 
of existing cardiovascular comorbidities prior to the Sunitinib treatment, which could explain 94 
the higher rate of cardiac events. 95 
 96 
The stress activated protein MKK7 belongs to the mitogen activated kinase kinase 97 
superfamily, which allows the cell to respond to exogenous and endogenous stimuli (Foltz et 98 
al. 1998). MKK7 activation of the downstream c-Jun N-terminal kinases (Tournier et al. 99 
2001) results in processes including: proliferation, differentiation, apoptosis and 100 
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tumorigenesis (Chang and Karin 2001). As MKK7 activity has been associated with 101 
cardiomyocyte damage (Liu et al. 2011), it would be interesting to assess changes in MKK7 102 
expression levels in the presence of Sunitinib at both transcriptional and post-translational 103 
levels at various age stages. Establishing an age dependent involvement of the MKK7 104 
pathway during Sunitinib-induced cardiotoxicity would lead to advance our understanding of 105 
the cardiac ageing pathways during stress stimuli and could lead to improve the anti-cancer 106 
treatment guidelines by implementing adjunct therapy options.    107 
 108 
This study investigates for the first time the involvement of the MKK7 pathway during 109 
Sunitinib-induced cardiotoxicity at various age stages via the assessment of cardiac function 110 
and injury using a Langendorff perfused rat heart model in: Adult rats (3 months), Middle-111 
aged rats (12 months) and Elderly rats (24 months). Furthermore, the differential expression 112 
patterns of cardiotoxicity-linked microRNAs miR-1, miR-27a, miR-133a and miR-133b is 113 
determined at the specific age groups.  114 
 115 
2. Materials and methods  116 
2.1. Materials 117 
Sunitinib malate and triphenyl-tetrazolium chloride were purchased from Sigma Aldrich 118 
(UK) and dissolved in dimethyl sulphoxide (DMSO) and stored at -20 °C. Krebs perfusate 119 
salts were from VWR International (UK) or Fisher Scientific (UK). Ambion 120 
MicroPoly(A)Puris kit, Ambion mirVana miRNA Isolation Kit, Reverse Transcription Kit, 121 
Applied Biosystems MicroRNA Reverse Transcription Kit, TaqMan Universal master mix II 122 
(no UNG), MKK7 mRNA primers, Applied Biosystems primers assays (U6, rno-miR-1, hsa-123 
miR-27a, hsa-miR-133a, and hsa-miR-133b) were purchased from Life Technologies (USA). 124 
The iTaq Universal SYBR Green Supermix was purchased from BioRad (UK). Phospho-125 
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MKK7 (Ser271/Thr275), Total MKK7 rabbit mAb antibodies and anti-rabbit IgG, HRP-126 
linked antibody and anti-biotin, HRP-linked antibody were purchased from Cell signaling 127 
technologies (UK). 128 
 129 
2.2. Animals and Ethics 130 
Adult male Sprague-Dawley rats (12-weeks old and 300-350 g in body weight ); were 131 
purchased from Charles River UK Ltd (UK) and housed suitably, received humane care and 132 
had free access to standard diet according to “The Guidance on the Operation of the Animals 133 
(scientific procedures) Act of 1986”. As aged animals > 6 month of age are not supplied by 134 
any Laboratory animal supplier we kept 30 12-weeks old rats until they were 12 month old 135 
and additional 30 12-weeks old rats until 24 months old, therefore the experiments using 3, 136 
12 and 24 month rat hearts at various intervals. Animals were selected at random for drug 137 
treatment groups and the collected tissue was blinded for infarct size assessment. The 138 
experiments were performed after approval of the protocol by the Coventry University Ethics 139 
Committee. All efforts were made to minimize animal suffering and to reduce the number of 140 
animals used in the experiments. A total of 79 animals were used for this study and the data 141 
from 63 rats were included (3 month: Tissue collection, Control n=6 and Sunitinib n=6, TTC 142 
collection, Control n=4 and Sunitinib n=5; 12 month: Tissue collection, Control n=7 and 143 
Sunitinib n=7, TTC collection, Control n=6 and Sunitinib n=6, 24 month: Tissue collection, 144 
Control n=5 and Sunitinib n=5, TTC collection, Control n=3 and Sunitinib n=3), while data 145 
from 15 rats were excluded from analysis due to the established haemodynamic exclusion 146 
criteria, which can be found in the “2.3. Langendorff perfusion model” section below. 147 
 148 
 149 
 150 
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2.3. Langendorff perfusion model  151 
Rats were sacrificed by cervical dislocation (Schedule 1 Home Office procedure) and the 152 
hearts were rapidly excised and placed into ice-cold Krebs Henseleit (KH) buffer (118.5 mM 153 
NaCl, 25 mM NaHCO3, 4.8 mM KCl, 1.2 mM MgSO4, 1.2 mM KH2PO4, 1.7 mM CaCl2, and 154 
12 mM glucose, pH7.4). The hearts were mounted onto the constant flow Langendorff system 155 
and retrogradely perfused with KH buffer. The pH of the KH buffer was maintained at 7.4 by 156 
gassing continuously with 95 % O2 and 5 % CO2 and maintained at 37 ± 0.5 °C using a 157 
water-jacketed organ chamber. Oxygen content of the perfused buffer has been monitored in 158 
previous studies, showing that the oxygen content is constant throughout the Langendorff 159 
experiment. The left atrium was removed and a latex iso-volumic balloon was carefully 160 
introduced into the left ventricle and inflated up to 5-10 mmHg. Functional recordings 161 
(LVDP and HR) were taken via a physiological pressure transducer and data recorded using 162 
Powerlab, AD Instruments Ltd. (UK). Coronary flow (CF) was measured by collecting and 163 
measuring the volume of perfusate for 1 minute. All haemodynamic parameters were 164 
measured at 5 minute intervals for the first 35 minutes of drug treatment, and then at 15 165 
minute intervals until the end of the experiment.   166 
 167 
Each Langendorff heart was perfused for 125 minutes with drug or vehicle in normoxic 168 
conditions after a 20 minutes stabilisation period to recover from the Langendorff cannulation 169 
procedure (Cooper et al. 2018; Sandhu et al. 2017). Generally, the hearts became stable after 170 
10 minutes, therefore all haemodynamic parameters were normalised to the last 10 minutes of 171 
the stabilisation period to take into account the variations between individual starting HR, 172 
LVDP and CF levels. Hearts were excluded in the study with: a LVDP below 80 mmHg or 173 
above 150 mmHg, a HR below 225 beats per minute or above 325 beats per minute, and a CF 174 
below 3.5 ml/g heart weigh or above  12.0 ml/g heart weight during the stabilisation period. 175 
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Haemodynamic effects are presented as a percentage of the last 10 minutes of the mean 176 
stabilisation period for each parameter to allow clear comparison across drug groups. The 177 
maximal change in LVDP, HR, and CF were calculated by calculating mean ± S.E.M. at the 178 
specific time points in Control and Sunitinib treated hearts in all three age groups (ie. 3, 12, 179 
and 24 month).  180 
 181 
Sunitinib malate (1 µM) was administered throughout the perfusion period. The dose of 1 µM 182 
Sunitinib was chosen in line with previous studies (Henderson et al. 2013). Langendorff 183 
perfused hearts treated with vehicle (i.e. DMSO) were recorded as Control group. The hearts 184 
were then weighed and either stored at -20 °C for triphenyl-tetrazolium chloride (TTC) 185 
staining or the left ventricular tissue was dissected free and immersed in RNAlater from 186 
Ambion (USA) for qRT-PCR or snap frozen with liquid nitrogen for Western blot analysis. 187 
 188 
2.4. Infarct size analysis  189 
Infarct size analysis was performed as described in our previous paper (Cooper et al. 2018). 190 
The mean of infarct to risk ratio for each treatment group and the mean ± S.E.M was plotted 191 
as a bar chart. The infarct size determination was randomized and blinded. 192 
 193 
2.5. Analysis of microRNA expression profiles 194 
MicroRNA was isolated from left ventricular tissue and the expression of housekeeping 195 
reference RNA U6 snRNA and target microRNAs rno-miR-1, hsa-miR-27a, hsa-miR-133a, 196 
and hsa-miR-133b was performed as described in our previous paper (Cooper et al. 2018). 197 
Analysis of qRT-PCR data of microRNAs was performed using the Ct values for U6 snRNA 198 
as reference for the comparison of the relative amount of microRNAs (rno-miR-1, hsa-miR-199 
27a, hsa-miR-133a and hsa-miR-133b). The values of each of the microRNA was calculated 200 
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to compare their ratios. The formula used was X0/R0=2^(CTR-CTX), where X0 is the original 201 
amount of target microRNA, R0 is the original amount of U6 snRNA, CTR is the Ct value for 202 
U6 snRNA, and CTX is the Ct value of the specific target microRNA. Averages of the Ct 203 
values for each sample group (Control and Sunitinib treated hearts) and each individual 204 
primer set were calculated and bar charts were plotted with mean ± S.E.M data.  The mean of 205 
the Control group was set as 1 for all microRNAs. 206 
 207 
2.6. Measurement of MKK7 mRNA expression 208 
Total mRNA was extracted from left ventricular tissue and expression of MKK7 and 209 
GAPDH was performed as described in our previous paper (Cooper et al. 2018). Analysis of 210 
qRT-PCR data of MKK7 mRNA were performed using the Ct values for GAPDH mRNA as 211 
reference for the comparison of the relative amount MKK7 mRNA. The formula used was 212 
X0/R0=2^(CTR-CTX), where X0 is the original amount of MKK7 mRNA, R0 is the original 213 
amount of GAPDH mRNA, CTR is the CT value for GAPDH mRNA, and CTX is the CT 214 
value for MKK7 mRNA. Averages of the Ct values for each sample group (Control and 215 
Sunitinib treated hearts) and MKK7 was calculated and bar charts were plotted with mean ± 216 
S.E.M.  The mean of the Control group was set as 1 for the MKK7 mRNA study.  217 
 218 
2.7. Western blot detection of phosphorylated MKK7  219 
Protein was isolated form left ventricular tissue and Western blot analysis using 220 
Phosphorylated (Ser271/Thr275)-MKK7 (p-MKK7) and total MKK7 was performed as 221 
described in our previous paper (Cooper et al. 2018). The relative changes in the p-MKK7 222 
protein levels were measured and corrected for differences in protein loading as established 223 
by probing for total MKK7. Results were expressed as a percentage of the density of 224 
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phosphorylated protein relative to the density of total protein using Image Lab 4.1 from 225 
BioRad (UK). 226 
 227 
2.8. Data analysis and statistics 228 
Results are presented as mean ± S.E.M. For haemodynamics data comparison of Control and 229 
Sunitinib groups the statistical analysis was done by Two-way repeated measures ANOVA 230 
test with the Bonferroni post hoc test. When comparing Control and Sunitinib within an age 231 
group significance of data sets was measured by 2-tailed Student’s t-test. When age groups 232 
were compared (i.e. 3 month vs 12 month, 3 month vs 24 month and 12 month vs 24 month) 233 
One-way ANOVA analysis with the LSD post hoc test was applied. We used the GraphPad 234 
Prism program version 5 and the IBM SPSS Statistics version 22 software for statistical 235 
analysis and p-values <0.05 were considered statistically significant. When comparing 236 
Control versus Sunitinib treatment statistical significance is shown as “*” on top or bottom 237 
(depending on increase or decrease) of the Sunitinib group. And when the Sunitinib treated 238 
age groups are compared, statistical significance is shown with “$” highlighted with a capped 239 
line linking the relevant age groups together. 240 
 241 
3. Results 242 
3.1. Haemodynamic parameters  243 
In this study, we recorded LVDP, HR, and CF to determine whether 1 µM Sunitinib induces 244 
signs of cardiac dysfunction during a 125 minute Langendorff perfusion in 3, 12 and 24 245 
month old rat hearts. 246 
 247 
 248 
 249 
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3.1.1. Sunitinib adversely affects LVDP in all age groups 250 
When treatment groups were normalised to the stabilisation period, Sunitinib treatment 251 
significantly decreased normalised LVDP in 3 and 24 month groups compared to their group 252 
Controls (Figures 1A-C). However, the onset of LVDP decline varied between the age 253 
groups. The maximal drop in LVDP from Control to Sunitinib treated hearts was observed at 254 
125 minutes in the 3 month group (Control: 85 ± 4 %; Sunitinib: 70 ± 4 %, P<0.05) and at 95 255 
minutes for the 24 month group (Control: 77 ± 1 %; Sunitinib: 56 ± 2 %, P<0.05) (Figures 1-256 
3). The largest decline in LVDP decline for the 12 month group at 125 minutes (Control: 80 ± 257 
2 %; Sunitinib: 69 ± 1 %), however, this was without statistical significance.  258 
 259 
3.1.2. Sunitinib alters HR in 3 and 12 month animals 260 
When the HR were normalised to the stabilisation period, HR was significantly decreased in 261 
the 3 month and 12 month groups when Control hearts were compared to hearts treated with 262 
Sunitinib. The HR for 24 month group remained stable during the Sunitinib treatment. 263 
Maximal drop in HR from Control to Sunitinib treated hearts was observed at 125 minutes in 264 
the 3 month group (Control: 100 ± 2 %; Sunitinib: 80 ± 5 %, P<0.001), at 125 minutes for the 265 
12 months group (Control: 98 ± 3 %; Sunitinib: 80 ± 3 %, P<0.01), and at a much earlier 266 
stage at 30 minutes for the 24 months group (Control: 98 ± 4 %; Sunitinib: 88 ± 6 %). At an 267 
early stage (5 and 10 minutes) HR in the 3 month group was increased significantly by 268 
Sunitinib treatment when compared to control hearts (p<0.05) (Figures 2A-C).  269 
 270 
3.1.3. Sunitinib treatment does not alter CF 271 
When the CF was normalised to the stabilisation period, CF was slightly increased in the 272 
three age groups where hearts were perfused with Sunitinib when compared to Control hearts. 273 
Maximal increase in CF from Control to Sunitinib treated hearts was observed at 10 min in 274 
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the 3 months group (Control: 89 ± 3 %; Sunitinib: 107 ± 4 %), at 5 min for the 12 months 275 
group (Control: 103 ± 2 %; Sunitinib: 119 ± 10 %), and at 50 min for the 24 month group 276 
(Control: 90 ± 2 %; Sunitinib: 93 ± 4 %) (Figures 3A-C).  277 
 278 
3.2. Infarct size assessment 279 
Sunitinib treatment produced significant increases in infarct size (normalised to heart weight) 280 
ratio in all age groups in an age dependent trend when compared to Control hearts (Figure 281 
4A-B). The infarct size to heart weight ratio was increased 5.1-fold in the 3 months group 282 
(Control: 3.29 ± 0.55 %; Sunitinib: 17.14 ± 0.39 %, P<0.001), increased 3.3-fold in the 12 283 
months group (Control: 3.06 ± 0.09 %; Sunitinib: 10.19 ± 0.84 %, P<0.001), and increased 284 
2.5-fold in the 24 months group (Control: 2.25 ± 0.21 %; Sunitinib: 5.53 ± 0.15 %, P<0.05) 285 
(Figure 4A-B). When the infarct size was normalised to that age group’s specific Control 286 
heart infarct size, we observed that the Sunitinib treatment resulted in a significantly higher 287 
infarct sizes in the 3 month group when compared to the 24 month group (P<0.01) (Figure 288 
4B). The infarct size in the Control hearts did not alter in the 3 age groups.  289 
 290 
3.3. microRNA expression profiles 291 
Here, we investigate the altered expression profiles of microRNAs miR-1, miR-27a, miR-292 
133a and miR-133b after Sunitinib-induced cardiotoxicity (Figure 5). The expression of miR-293 
1 is not altered significantly in any of the age groups in response to Sunitinib treatment, 294 
compared to specific age group Controls. A significant reduction in miR-27a expression was 295 
observed in all 3 age groups response to Sunitinib treatment, compared to specific age group 296 
Controls (0.4 fold decrease in 3 months group, P<0.001; 0.43 fold decrease in 12 months 297 
group, P<0.05; 0.69 fold decrease in 24 months group, P<0.05). The expression of miR-133a 298 
and miR-133b followed the same pattern in each age group; Sunitinib treatment showed a 299 
13 
 
significant increase in miR-133a and miR-133b levels, in the 3 months group (miR-133a: 300 
2.70 fold increase, P<0.001; miR-133b: 3.79 fold increase, P<0.01) and a significant decrease 301 
in the 24 months group (miR-133a: 0.70 fold decrease, P<0.001; miR-133b: 0.64 fold 302 
decrease, P<0.01) compared to specific age group Controls (Figure 5). 303 
 304 
3.4. MKK7 mRNA expression 305 
MKK7 mRNA profiling in response to Sunitinib treatment revealed a significant decrease in 306 
MKK7 mRNA in 3 month old rats (~ 3 fold decrease, P<0.05) and an increase in MKK7 307 
mRNA in 24 month old rats (~ 12 fold increase, P<0.01) (Figure 6). When the Sunitinib-308 
induced alteration of MKK7 mRNA was normalised to Control for each age group, we 309 
observed an age dependent increase in MKK7 mRNA in 12 month and 24 month groups 310 
when compared to the 3 month group (P<0.001) (Figure 6). 311 
 312 
3.5. Phosphorylated MKK7 protein expression profile 313 
We investigated the effect of Sunitinib induced cardiac injury on MKK7 phosphorylation 314 
levels in different age groups. In the 3 month group p-MKK7 levels were significantly 315 
decreased after Sunitinib treatment, compared to Control (Control: 79 ± 8 %; Sunitinib: 46 ± 316 
2 %, P<0.05). Contrarily, in 12 month group there was a significant increase in p-MKK7 317 
levels after Sunitinib treatment, compared to Control (Control: 56 ± 3 %; Sunitinib: 71 ± 5 %, 318 
P<0.05). There were no changes in p-MKK7 levels in 24 month group following Sunitinib 319 
treatment compared to Control hearts (Figure 7A). There was a significant increase in p-320 
MKK7 levels in the 12 month group compared to 3 month group when the Sunitinib 321 
treatment was normalised to specific age group Controls (~2 fold increase, P<0.01), and a 322 
significant decrease in the 24 month group compared to the 12 month group (~ 2/3 fold 323 
decrease, P<0.05) (Figure 7B). 324 
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4. Discussion 325 
In the clinic, the level of cardiotoxicity generated by Sunitinib treatment is largely 326 
underestimated (Schmidinger et al. 2008). This is highlighted by the increasing number of 327 
cancer survivors, developing acute and delayed toxicities later in life (Lipshultz et al. 2013). 328 
Age is a well-established risk factor which may predispose a patient to cardiotoxicity. As 329 
Sunitinib treatment is administered to patients at a variety of ages (from paediatrics to elderly 330 
patients), it is important to identify the level of Sunitinib-induced cardiotoxicity produced in 331 
various age groups (Hutson et al. 2014; Janeway et al. 2009).  332 
 333 
Cardiovascular events have been reported during and after Sunitinib treatment in the clinic 334 
and in in vitro settings (Di Lorenzo et al. 2009; Sandhu et al. 2017). In the clinic, doctors are 335 
advised to monitor patients who display cardiac risk factors and/or history of coronary artery 336 
disease, the left ventricular ejection fraction and also for hypertension development in 337 
patients undertaking oral Sunitinib treatment, however, most patients are not monitored for 338 
adverse cardiovascular reactions to Sunitinib treatment (Kollmannsberger et al. 2007). This 339 
study shows that ageing strengthens the hearts ability to resist Sunitinib-induced heart tissue 340 
damage, however, the cardiac function is dramatically impaired (i.e. haemodynamic 341 
parameter LVDP). Younger animals appear to be more sensitive to toxicities in early stages 342 
of treatment, however, all age groups were found to have Sunitinib-induced cardiotoxicity. 343 
Furthermore, the stress activated MKK7 has shown to have a role in the level of Sunitinib-344 
induced cardiotoxicity (Cooper et al. 2018).  345 
 346 
4.1. Sunitinib is cardiotoxic in all three age groups 347 
Here we investigated age-associated differences in Sunitinib-induced cardiotoxicity, by 348 
measuring changes in haemodynamic parameters (i.e. LVDP, HR, and CF) and the level of 349 
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heart tissue infarction in 3, 12, and 24 month rats. The concentration of 1 µM Sunitinib was 350 
chosen in line with the clinically relevant study by Goodman et al. 2007, where patients 351 
suffering from Imatinib refractory or intolerant gastrointestinal stromal tumour, and patients 352 
with metastatic renal cell carcinoma where treated with Sunitinib. The steady state blood 353 
concentrations of Sunitinib was reported to be in the range of 0.1 – 1.0 μM (Goodman et al. 354 
2007; Henderson et al. 2013). 355 
 356 
It should be noted that our study shows the direct and acute cardiac effect of Sunitinib 357 
perfusion of rat hearts. As the isolated Langendorff model detects the acute effect of 358 
Sunitinib on the myocardium, systemic vasculature and neurohormonal effects of Sunitinib 359 
are thus excluded. The study by Mooney et al., showed the link between acute Sunitinib-360 
induced cardiotoxicity and calcium/calmodulin-dependent protein kinase II (CaMKII) 361 
activity. CaMKII is a key regulator of cardiac contractile function and dysfunction. Their 362 
study showed that acute administration of Sunitinib resulted in decreased LVDP and systolic 363 
and diastolic blood pressure, and this was correlated with decreased CaMKII activity. Thus, 364 
Sunitinib’s lack of kinase selectivity could result in impacting CaMKII at an acute treatment 365 
stage (Mooney et al. 2015). The present study found significant declines in LVDP in all 3 age 366 
groups following treatment with Sunitinib. LVDP is a measurement of cardiac function (i.e. 367 
force of contraction) in terms of pressure in the left ventricle, where LV diastolic pressure is 368 
subtracted from LV systolic pressure (i.e. LVDP = left ventricular systolic pressure – left 369 
ventricular diastolic pressure) (Kolwicz and Tian 2010). On the other hand left ventricular 370 
ejection fraction (LVEF) represents the heart’s pumping efficiency, and is calculated by 371 
taking the fraction of chamber volume ejected in systole (i.e. stroke volume (SV = end-372 
diastolic volume – end-systolic volume)) in relation to the volume of the blood in the 373 
ventricle at the end of diastole (i.e. end-diastolic volume) (LVEF = SV/end-diastolic volume 374 
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x 100) (Kosaraju and Makaryus 2018). Although LVDP and LVEF are calculated using 375 
different parameters, they will be correlated as both represent the cardiac function depending 376 
on similar inputs. Interestingly, the 24 month group produced the largest maximum drop in 377 
LVDP (Figure 1C). Left ventricular dysfunction is one of the main adverse cardiac side-378 
effects of Sunitinib, after hypertension (Chu et al. 2007). During a 3 year study following 48 379 
patients treated with Sunitinib, Telli et al. reported significant declines in left ventricular 380 
ejection fraction in 21 % of patients, and 15 % of patients developed symptoms of heart 381 
failure (Telli et al. 2008). Chu et al. also demonstrated deterioration of myocardial 382 
contractility in response to Sunitinib treatment (Chu et al. 2007). Left ventricular dysfunction 383 
and a decline in cardiac contractility have been linked to mitochondrial dysfunction, which 384 
occurs as a result of the inhibition of ribosomal S6 kinase and AMP-activated protein kinase 385 
by Sunitinib (Hasinoff et al. 2008). The heart has a high energy demand and through ageing, 386 
essential cellular processes - including autophagy - become dysfunctional (Peart et al. 2014). 387 
This results in an accumulation of impaired cellular machinery, such as mitochondria. In turn, 388 
this reduces the level of ATP available for cardiomyocytes and reduces heart function, both 389 
of which have been linked to age associated heart failure (Moyzis et al. 2015). The younger 390 
hearts may facilitate a more efficient process of autophagy and cell death pathways, which 391 
prevent the accumulation of dysfunctional mitochondrial and protein signalling (Zhao et al. 392 
2010). It is likely that Sunitinib caused a further depletion in ATP levels in aged hearts 393 
through the inhibition of AMPK, which lead to a decline in left ventricular function (Force et 394 
al. 2007). However, this needs to be investigated in further detail. 395 
 396 
In response to Sunitinib treatment, an initial early significant increase in HR at 5 and 10 397 
minutes was found in the 3 months group (Figure 2A). In patients, initial atrial fibrillation 398 
with rapid ventricular responses as well as tachycardia have been identified in the first cycle 399 
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of Sunitinib treatment (Grossmann et al. 2008). This highlights the instant cardiovascular 400 
effects Sunitinib can generate.  However, after 15 minutes of Sunitinib perfusion both, the 3 401 
month and 12 month group demonstrated significant declines in HR (Figure 2A-B). 402 
Henderson et al. showed a dose-dependent decline in HR under ischemic conditions in 403 
Langendorff studies (Henderson et al. 2013). In the clinic declines in HR are a common side 404 
effect of Sunitinib treatment (Azizi et al. 2008). Bello et al. demonstrated that Sunitinib 405 
induces QT-interval prolongation in patients and there is a dose-dependent increased risk of 406 
ventricular arrhythmias with Sunitinib treatment (Bello et al. 2009). At a cellular level 407 
Sunitinib had been shown to block the cardiac human ether-a-go-go related gene (ERG) 408 
channel which is associated with long QT syndrome (Doherty et al. 2013). Interestingly, 409 
Sunitinib treatment did not produce significant declines in HR in the 24 month group (Figure 410 
2C). Ageing can produce an accumulation of compensatory cardiomyocyte remodelling in the 411 
heart (Gosse 2005). This could be due the 24 months control group having a much lower HR 412 
at baseline (Table 3). Over time, the heart enlarges in response to increase in haemodynamic 413 
load, neuro-hormonal and pro-hypertrophic signalling (Gosse 2005). Remodelling 414 
fundamentally begins with molecular changes, such as altered cell growth regulation and 415 
protein expression. This results in impairment of myocardial performance and causes a lower 416 
heart rate (Lupon et al. 2015).  417 
 418 
It should be noted that the maximal decrease in LVDP and HR of hearts treated with 419 
Sunitinib when compared to Control, for the 24 month group did not occur at the end time 420 
point of 125 mins as observed for the 3 and 12 months groups, instead LVDP maximal 421 
decrease for 24 month group occurred at 95 mins, while HR maximal decrease occurred at 30 422 
mins. This inconsistency in time is most like due to biological variability of the aged hearts.  423 
 424 
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Furthermore, we investigated the level of Sunitinib-induced infarct size of treated hearts in 3, 425 
12, and 24 month rats. All of the age groups demonstrated significant increases in infarct size 426 
after 1 µM Sunitinib treatment, compared to control hearts (Figures 4A-B). Henderson et al. 427 
measured troponin levels as a marker for myocyte injury, and the group demonstrated 428 
significant increases in troponin levels release from an isolated rat heart model treated with 1 429 
µM Sunitinib (Henderson et al. 2013). In a study using induced pluripotent stem cell-derived 430 
cardiomyocytes, Cohen et al. demonstrated that Sunitinib treatment resulted in a loss of ATP 431 
and increased oxidized glutathione, which was thought to induce apoptosis (Cohen et al. 432 
2011). In addition to this, 1 µM Sunitinib treatment on isolated human myocardium tissue 433 
and isolated mouse left ventricular myocytes, was shown to produce a significant decline in 434 
intracellular Ca2+ levels and an increase in levels of reactive oxygen species generation, 435 
which can cause apoptosis (Rainer et al. 2012). Interestingly, in the present study, the 3 436 
months group produced a much larger infarct size than both the 12 and 24 month groups 437 
(Figures 4A-B). It has been established that younger patients (< 20 years) are more 438 
susceptible to cardiac injury during and after cancer therapy (Hancock et al. 1993). QT-439 
interval prolongation and a decrease in ejection fraction has been reported in children during 440 
the first cycle of Sunitinib treatment (Dubois et al. 2011). This suggests that younger hearts 441 
have an initial increase in sensitivity to Sunitinib-induced cardiotoxicity. The 12 and 24 442 
month groups had a smaller infarct sizes than 3 month old rats (Figure 4B). Capitanio et al. 443 
demonstrated that elements of heart protection could be present in disease-free ageing of 444 
Sprague-Dawely rats. There was an activation of cellular protective mechanisms such as a 445 
reduction in reactive oxygen species generation, resistance to apoptosis and inhibition of 446 
mitochondrial permeability transition pore opening (Capitanio 2016). Therefore, the 12 and 447 
24 months Sunitinib treated groups could have existing cardioprotective resistance to cell 448 
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death and tissue injury through ageing, and thus would not be greatly affected by 2 hours of 449 
Sunitinib therapy. 450 
 451 
However, the huge decline in LVDP of the 24 month group is indicative of cardiovascular 452 
dysfunction. Ageing lowers the threshold for development of cardiovascular diseases. The 453 
cardiac defence mechanisms protecting the heart from injuries and the injury repair pathways 454 
become defective. Furthermore, the cardiac structure alters with ageing, leading to vascular 455 
stiffening, enlargement of left ventricular wall thickness, and fibrosis. In addition to this, 456 
there are some key functional changes in the ageing heart that lead to a decline in the reserve 457 
capacity, which impairs the heart’s capacity to function properly during the strained workload 458 
(Strait and Lakatta 2012). With this in mind the steep decline in LVDP observed in Sunitinib 459 
treated aged animals (i.e. 27 % in 24 months) compared to younger ones (i.e. 17 % in 3 460 
months) could be a result of dysfunctional structural and functional changes in aged animals. 461 
These dysfunctional structural and functional changes could also explain why the infarct size 462 
was more predominant in the Sunitinib treated younger animals (5.1 fold increase) compared 463 
to aged animals (2.5 fold increase), as Sunitinib exposure for 2 hours might not have been 464 
adequate to induce infarct in stiff and enlarged cardiac tissue. Further investigation into the 465 
structural and functional properties of aged heart tissue in response to Sunitinib treatment is 466 
required to establish why Sunitinib treatment caused the hearts of 24 month rats to produce 467 
reductions in function, yet produced smaller infarct sizes than younger animals when 468 
compared to untreated hearts. 469 
 470 
4.2. Key cardiac injury linked microRNAs are altered by Sunitinib treatment 471 
Short non-coding RNA microRNAs carry out the negative regulation of mRNA transcripts by 472 
repressing translation (Bartel 2004). Specific microRNAs expression patterns have been 473 
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linked to cardiomyocyte differentiation and in response to stress (Babiarz et al. 2012) and 474 
have also been shown to be differentially expressed during the development of heart failure 475 
(Thum et al. 2007). Furthermore, microRNAs are critical regulators in the expression and 476 
function of eukaryotic genomes. Changes in the expression of certain microRNAs could be 477 
indicative of specific diseases or medical conditions (Lu et al. 2008). The expression profiles 478 
of miR-1, miR-27a, miR-133a and miR-133b tend to be altered during cardiac injury and 479 
during the progression of heart failure (Akat et al. 2014; Tijsen et al. 2012). We show 480 
Sunitinib induced changes in expression profiles of miR-27a, miR-133a and miR-133b in the 481 
3 age groups investigated. 482 
 483 
In response to Sunitinib, miR-27a was reduced in all age groups (Figure 5). miR-27a has 484 
been shown to down-regulate FOXO-1 protein, a transcription factor which regulates genes 485 
involved in the apoptotic response, cell cycle, and cellular metabolism (Guttilla and White 486 
2009). It has also been observed that over expression of FOXO1 resulted in decreased cell 487 
viability because of inhibition of cell cycle and induction of apoptosis. A down regulation of 488 
miR-27a has been linked to an increased sensitivity to Adriamycin induced apoptosis (Zhang 489 
et al. 2010). This suggests that miR-27a is an effective regulator of apoptosis. In coronary 490 
sinus samples miR-27a is significantly downregulated in heart failure patients (Marques et al. 491 
2016). The significant decrease in miR-27a expression during Sunitinib treatment during the 492 
current study follows the same trend in expression as patients with heart failure and apoptosis 493 
at a cellular level, which could suggest that a down-regulation of miR-27a predicts an 494 
increase in apoptosis or heart tissue damage within the heart, as we have shown an increase in 495 
infarct size in all age groups.  496 
 497 
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Interestingly, miR-133a and miR133b are both significantly upregulated in 3 months group, 498 
but downregulated in 24 months in response to Sunitinib treatment (Figure 5). In our previous 499 
Sunitinib studies have seen similar findings with either significant or a strong tendency 500 
towards an increased expression of miR-133a and miR-133b after Sunitinib administrating 501 
during Langendorff perfused hearts compared to vehicle treated hearts (Cooper et al. 2018; 502 
Sandhu et al. 2017). miR-133a has a partial complimentary target site in the 3’-untranslated 503 
region of the human ERG potassium channel transcripts, implying that miR-133a 504 
overexpression inhibits the ERG potassium channel expression (Xiao et al. 2007). A 505 
reduction in ERG potassium channel expression results in delayed myocyte repolarization, 506 
which is attributed to a long QT interval (Xiao et al. 2007). Therefore, the increase in miR-507 
133a found in the 3 months group suggests an increase in ERG inhibition, which could be 508 
responsible for a slower heart rate. Sunitinib treatment of both 12 months and 24 months 509 
groups demonstrated significant reductions in miR-133a. This could suggest that Sunitinib 510 
causes attenuation of the ERG potassium channel expression by miR-133a may have taken 511 
place (Bello et al. 2009).   However, Sunitinib also induced significant reductions in HR in 512 
the 12 month group. This suggests that alternate mechanisms to Sunitinib-induced ERG 513 
inhibition could be occurring in older animals. This highlights the complexity of Sunitinib-514 
induced HR reductions at different ages. 515 
 516 
In addition, miR-133a has been shown to be upregulated during oxidative stress (Izarra et al. 517 
2014). In cardiomyocytes miR-133b has been shown to be upregulated during apoptosis, but 518 
downregulated during hypertrophy (Ramasamy et al. 2015). This could suggest that Sunitinib 519 
treatment resulted in increased levels of oxidative stress and cell death in the 3 month group, 520 
which resulted in a larger infarct size compared to 12 month and 24 month groups. 521 
MicroRNAs have previously been shown to be differentially expressed when young rodent 522 
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hearts are compared to aged rodent hearts (Zhang et al. 2012). Perhaps, ageing provides 523 
alternate signalling mechanisms which reduce levels of Sunitinib-induced cell death or heart 524 
tissue damage. This needs to be investigated further. 525 
 526 
4.3. The level of MKK7 transcription and protein phosphorylation is greatly affected by 527 
Sunitinib treatment and the age of rat hearts treated 528 
MKK7 is a stress signalling protein with a vital role in cellular stress response and is 529 
fundamental in regulating cell survival, proliferation and cell death (Foltz et al. 1998). MKK7 530 
has previously been shown have an important role in protecting the heart from heart failure 531 
(Liu et al. 2011), and furthermore MKK7 has been shown to be involved in the development 532 
of reductions in haemodynamic parameters and an increase in infarct size in 3 month old rats 533 
(Cooper et al. 2018). Alterations in the level of MKK7 protein activation have been shown to 534 
be age specific (Jiang et al. 1993). As Sunitinib produces adverse effects in the heart (Ewer et 535 
al. 2014; Gupta and Maitland 2011), it would be important to establish whether MKK7 levels 536 
are altered in response to Sunitinib treatment in ageing animals. Here we show the level of 537 
MKK7 transcription and MKK7 protein phosphorylation is affected by ageing and Sunitinib 538 
treatment.  539 
 540 
Firstly we investigated whether MKK7 mRNA levels are altered in response to Sunitinib-541 
induced cardiac injury. In the 3 months group Sunitinib treatment leads to a significant 542 
reduction in both MKK7 mRNA and phosphorylated MKK7, compared to Control (Figures 6 543 
and 7A). Sunitinib treatment significantly increased the levels of MKK7 mRNA in the 12 544 
month group and there was a tendency for an increased in MKK7 mRNA levels in the 24 545 
month group (Figure 6). 546 
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Younger animals were shown to have a marked reduction of active MKK7 during Sunitinib 547 
treatment when compared to older animals. This could be a result of the younger animals not 548 
being fully developed for stress activated cellular signalling pathways, which could have 549 
resulted in activation of cell death pathways, which led to the huge increase in infarct size 550 
compared to the older animals. In a study by Zhang et al., it was shown that ageing resulted 551 
in selective upregulation of stress protein genes and transcripts involved in cell growth, death, 552 
and signalling, namely extracellular signal-regulated kinase 2/3, c-Jun N-terminal kinase 2, 553 
caspase 6, cyclin-dependent kinase 4, proliferating cell nuclear antigen, and heterogeneous 554 
nuclear ribonucleoprotein K in Fischer 344 rats. Furthermore, they detected a downregulation 555 
of genes involved in antioxidant defences and drug metabolism, including glutathione 556 
transferase subunit P, cytochrome P-450 VII, nicotinamide adenine dinucleotide phosphate 557 
cytochrome P-450 reductase, bleomycin hydrolase, N-oxide forming dimethylaniline 558 
monooxygenase 1, and serum paraoxonase (Zhang et al. 2002).  559 
 560 
We have observed a decrease in Sunitinib-induced infarct size in aged animals when 561 
compared to young animals (Figure 4A). The MKK expression after Sunitinib treatment at 562 
transcriptional level however increases in aged animals when compared to young animals 563 
(Figure 6), and the phosphorylated level of MKK7 after Sunitinib treatment is also increased 564 
from 3 to 12 months rats, while the phosphorylated MKK7 level is not altered by Sunitinib in 565 
the 24 month rats (Figure 7A). Liu et al., demonstrated that pressure overload in MKK7 566 
knockout mice was associated with elevated cardiomyocyte apoptosis and enhanced 567 
deterioration of ventricular function (Liu et al. 2011). The study by Liu et al. supports our 568 
current and previous findings, as the reduction in MKK7 transcription is associated with 569 
increased sensitivity to Sunitinib-induced cardiotoxicity in 3 month animals, while an 570 
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increase in MKK7 transcription is associated with decreased sensitivity to Sunitinib-induced 571 
cardiotoxicity in older animals (Figures 4A and 7A) (Cooper et al. 2018).  572 
 573 
Interestingly, Hsieh et al. 2003, also demonstrated an increased level of MKK7 activation in 574 
response to reactive oxygen species generation in 24 month old mice compared to 3 month 575 
old mice (Hsieh et al. 2003). Previously, over-expression of MKK7 has also been shown to 576 
produce characteristic features of myocardial hypertrophy, which may have contributed to the 577 
loss of contractile function and cardiomyocyte viability following ischaemia/reperfusion 578 
injury (Wang et al. 1998). In turn, studies investigating cardiac hypertrophy have shown 579 
activated MKK7 levels to be significantly higher than in controls (Wang et al. 2008). This 580 
could suggest that the increase in MKK7 mRNA in the 12 month and 24 month groups and 581 
phosphorylated MKK7 in the 12 month group could indicant a hypertrophic response to 582 
Sunitinib treatment. However, Sunitinib treatment in the 24 month group did not alter p-583 
MKK7 levels, but significantly increased MKK7 mRNA levels (Figures 6 and 7A). Perhaps 584 
overtime cells adapt cellular processes, including MKK7 signalling, to increase resistance to 585 
initiation of cell death pathways (Gosse 2005).  586 
 587 
4.4. Conclusion 588 
Ageing induces changes to the morphology, protein signalling and effective functioning of 589 
the heart. It is therefore important to investigate the potential cardiovascular effects of drugs 590 
in models of ageing. Here we have shown that ageing is associated with a more robust 591 
defence against Sunitinib-induced cardiac infarct, as younger animals display a significantly 592 
higher Sunitinib-induced cardiac infarct sizes compared to the older animals. Interestingly, 593 
we also showed that aged animals had a much more profound decrease in LVDP compared to 594 
younger animals, thus emphasising that ageing does alter the anti-cancer therapy-induced 595 
25 
 
cardiotoxicity in a defined and complex pattern, which must be investigated further at an 596 
intracellular level in order to pinpoint key pathways involved. Discovering the role of these 597 
key pathways involved in the development of Sunitinib-induced cardiotoxicity in elderly 598 
cancer patients could lead to the identification of novel and impactful adjunct therapy 599 
regimes to be implemented along with anti-cancer treatment, which will increase the outcome 600 
rate and quality of life in the elderly cancer patients. 601 
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Figures and legends 829 
 830 
Figure 1: Representation of changes in LVDP measured during Langendorff experiments 831 
over time relative to the stabilisation period in Control and 1 µM Sunitinib treated hearts. A) 832 
3 month (3m) (n=9 per group), B) 12 month (12m) (n=6 per group), and C) 24 month (24m) 833 
(n=3-5 per group). Data expressed as mean ± S.E.M. Statistics: Two-way repeated measures 834 
ANOVA test with the Bonferroni post hoc test comparing Control and Sunitinib treated 835 
hearts: * = P<0.05 and ** = P<0.01. 836 
36 
 
 837 
Figure 2: Representation of changes in HR measured during Langendorff experiments over 838 
time relative to the stabilisation period in Control and 1 µM Sunitinib treated hearts. A) 3 839 
month (3m) (n=9 per group), B) 12 month (12m) (n=6 per group), and C) 24 month (24m) 840 
(n=3-5 per group). Data expressed as mean ± S.E.M. Statistics: Two-way repeated measures 841 
ANOVA test with the Bonferroni post hoc test comparing Control and Sunitinib treated 842 
hearts: ** = P<0.01 and *** = P<0.001. 843 
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 844 
Figure 3: Representation of changes in CF measured during Langendorff experiments over 845 
time relative to the stabilisation period in Control and 1 µM Sunitinib treated hearts. A) 3 846 
month (3m) (n=9 per group), B) 12 month (12m) (n=6 per group), and C) 24 month (24m) 847 
(n=3-5 per group). Data expressed as mean ± S.E.M. 848 
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 849 
Figure 4:  Infarct to whole heart ration assessment. Acetate sheet traces of infarct 850 
(blue/black) versus whole heart (red) shown above the graph. The hearts were drug perfused 851 
with 1 µM Sunitinib for 125 minutes in an isolated Langendorff heart model with the 852 
following groups: Control and 1 µM Sunitinib in 3 month (3m) (n=4-5 per group), 12 month 853 
(12m) (n=6 per group), and 24 month (24m) (n=3 per group). A) Infarct to whole heart ratio 854 
assessment for all three individual age groups for both Control and Sunitinib treated hearts, 855 
B) Infarct to whole heart ratio assessment as a percentage of Control hearts. Data expressed 856 
as mean ± S.E.M. Statistics: A) 2-tailed Student’s t-test comparing Control and Sunitinib 857 
treated hearts (* = P<0.05 and *** = P<0.001). B) One-way ANOVA using LSD post hoc 858 
test (comparing 3 month versus 12 month, 3 month versus 24, and 12 month versus 24 month 859 
month): $$ = P<0.01. 860 
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 861 
Figure 5: The effect of 1 µM Sunitinib on expression of cardiac damage specific microRNAs 862 
following 125 minute drug perfusion in an isolated Langendorff heart model. The qRT-PCR 863 
results are shown as a ratio of target microRNA normalised to U6 with Control group 864 
microRNA ratio set as 1 of microRNAs miR-1, miR-27a, miR-133a, and miR-133b presented 865 
on a log scale. Groups: 3 month (3m) (n=6 per group), 12 month (12m) (n=7 per group), 24 866 
month (24m) (n=5 per group). Data expressed as mean ± S.E.M. Statistics: 2-tailed Student’s 867 
t-test comparing Control and Sunitinib treated hearts in the specific age group (* = P<0.05, 868 
** = P<0.01, and *** = P<0.001). One-way ANOVA using LSD post hoc test (comparing 3 869 
month versus 12 month, 3 month versus 24, and 12 month versus 24 month month): $$$ = 870 
P<0.001. 871 
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 872 
Figure 6: The qRT-PCR assessment of MKK7 mRNA expression levels in an isolated 873 
Langendorff heart model after 1 µM Sunitinib treatment. The qRT-PCR results are shown as 874 
a ratio of MKK& mRNA in Sunitinib treatment normalised to GAPDH mRNA with Control 875 
group ratio set as 1 presented on a log scale. Groups: 3 month (3m) (n=6 per group), 12 876 
month (12m) (n=7 per group), 24 month (24m) (n=5 per group). Data expressed as mean ± 877 
S.E.M. Statistics: 2-tailed Student’s t-test comparing Control and Sunitinib treated hearts in 878 
the specific age group (* = P<0.05 and ** = P<0.01). One-way ANOVA using LSD post hoc 879 
test (comparing 3 month versus 12 month, 3 month versus 24, and 12 month versus 24 month 880 
month): $$$ = P<0.001. 881 
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 882 
Figure 7: Western blot assessment of MKK7 phosphorylation levels of in an isolated 883 
Langendorff heart model after 125 minutes of 1 µM Sunitinib perfusion. Groups: 3 month 884 
(3m) (n=3 per group), 12 month (12m) (n=3 per group), 24 month (24m) (n=3 per group). A) 885 
p-MKK7 levels represented as a percentage of total-MKK7 found in the Control and 886 
Sunitinib treated heart tissue. B) The Sunitinib treatment groups normalised to the Control of 887 
the respective age groups to allow for comparison of p-MKK7levels within the three age 888 
groups. Data expressed as mean ± S.E.M. Statistics: A) 2-tailed Student’s t-test comparing 889 
Control and Sunitinib treated hearts in the specific age group (* = P<0.05). B) One-way 890 
ANOVA using LSD post hoc test (comparing 3 month versus 12 month, 3 month versus 24, 891 
and 12 month versus 24 month month): $ = P<0.05 and $$ = P<0.01. 892 
  893 
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Tables for Supplementary data: 894 
 895 
Table 1 - Raw data values of left ventricular developed pressure (LVDP) in mmHg obtained 896 
during 125 minutes of Langendorff perfused Control or Sunitinib (1 µM) hearts. Groups: 3 897 
month (n=9), 12 month (n=6), and 24 month (Control: n=3; Sunitinib: n=5). Data expressed 898 
at mean ± S.E.M. Two-way ANOVA statistical analysis with Tukey post hoc test: 12 month 899 
and 24 month versus 3 month control: a (p<0.05) and aa (p<0.01); 24 month versus 12 month 900 
control: b (p<0.05); 12 month and 24 month versus 3 month Sunitinib: A (p<0.05); 24 month 901 
versus 12 month Sunitinib: B (p<0.05), BB (p<0.01), and BBB (p<0.001).  902 
 903 
LVDP Control Sunitinib 
Time 3 month 12 month 24 month 3 month 12 month 24 month 
0 112.15 ± 3.09 138.50 ± 8.22 118.77 ± 14.43 113.21 ± 3.13 143.82 ± 4.96A 125.82 ± 12.92 
5 123.77 ± 2.96 136.55 ± 5.66 109.83 ± 16.70 138.17 ± 8.01 142.95 ± 5.84 112.06 ± 5.28 
10 119.93 ± 2.90 142.85 ± 16.26 119.97 ± 11.63 131.19 ± 7.22 141.67 ± 6.34 104.18 ± 13.19B 
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 904 
  905 
15 116.01 ± 3.03 140.88 ± 14.27 122.55 ± 8.38 122.76 ± 8.44 140.18 ± 6.15 95.21 ± 11.56BB 
20 116.98 ± 3.46 144.30 ± 11.30 110.01 ± 12.90 112.67 ± 5.98 133.40 ± 5.98 94.77 ± 13.00BB 
25 112.87 ± 3.58 145.90 ± 14.50a 112.78 ± 12.22 112.12 ± 4.99 134.52 ± 4.56 97.86 ± 13.85B 
30 115.84  ± 3.50 145.35 ± 14.71a 115.38 ± 13.53 106.30 ± 5.56 135.07 ± 4.08A 92.37 ± 11.87BB 
35 113.97 ± 4.49 142.13 ± 13.07 111.74 ± 12.62 106.92 ± 3.87 135.93 ± 5.02A 90.16 ± 10.83BBB 
50 110.06 ± 6.35 142.68 ± 9.65a 101.84 ± 12.23b 96.97 ± 5.89 127.00 ± 5.34A 86.77 ± 9.05BB 
65 107.63 ± 7.18 136.48 ± 10.89a 92.16 ± 11.38a,b 92.67 ± 4.65 124.89 ± 6.41A 74.53 ± 4.21BBB 
80 101.16 ± 5.24 134.70 ± 14.11aa 90.00 ± 9.41b 91.29 ± 4.23 116.96 ± 4.93 71.43 ± 6.19BB 
95 98.19 ± 2.23 132.35 ± 8.40aa 90.45 ± 7.44b 92.84 ± 5.48 113.52 ± 6.04 69.83 ± 6.02BB 
110 93.20 ± 2.76 128.00 ± 9.44aa 89.25 ± 7.40b 84.55 ± 4.01 105.05 ± 3.70 72.47 ± 10.48B 
125 92.71 ± 2.31 123.65 ± 6.67a 86.70 ± 7.46 80.16 ± 3.97 97.35 ± 2.86 69.44 ± 8.92 
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Table 2 - Raw data values of heart rate (HR) in beats/minute obtained during 125 minutes of 906 
Langendorff perfused Control or Sunitinib (1 µM) hearts. Groups: 3 month (n=9), 12 month 907 
(n=6), and 24 month (Control: n=3; Sunitinib: n=5). Data expressed at mean ± S.E.M. Two-908 
way ANOVA statistical analysis with Tukey post hoc test: 12 month and 24 month versus 3 909 
month control: a (p<0.05) and aa (p<0.01); 24 month versus 12 month control: b (p<0.05) 910 
and bb (p<0.01); 12 month and 24 month versus 3 month Sunitinib: A (p<0.05); 24 month 911 
versus 12 month Sunitinib: BB (p<0.01). 912 
HR Control Sunitinib 
Time 3 month 12 month 24 month 3 month 12 month 24 month 
0 262.22 ± 6.80 262.00 ± 19.17 196.67 ± 10.80a 275.56 ± 7.93 242.00 ± 13.42 224.00 ± 19.56 
5 257.78 ± 6.56 270.00 ± 19.04 196.67 ± 8.16b 271.11 ± 9.91 238.00 ± 13.87 220.00 ± 23.18 
10 256.67 ± 7.29 262.00 ± 22.75 190.00 ± 7.07a,b 262.22 ± 8.06 240.00 ± 13.23 222.00 ± 24.60 
15 256.67 ± 6.85 262.00 ± 19.81 196.67 ± 10.80a 255.56 ± 7.31 234.00 ± 9.08 220.00 ± 21.51 
20 256.67 ± 6.85 252.00 ± 18.17 193.33 ± 8.16a 250.00 ± 7.50 228.00 ± 8.94 214.00 ± 23.87 
25 262.22 ± 7.86 252.00 ± 20.43 200.00 ± 14.14a 256.67 ± 9.35 234.00 ± 5.70 212.00 ± 20.74 
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  913 
30 262.22 ± 8.06 254.00 ± 23.08 193.33 ± 14.72a 248.89 ± 7.59 226.00 ± 4.47 208.00 ± 21.62 
35 271.11 ± 7.80 254.00 ± 23.08 190.00 ± 7.07aa 255.56 ± 7.31 234.00 ± 8.37 214.00 ± 19.56 
50 256.67 ± 7.71 252.00 ± 18.17 180.00 ± 7.07aa,b 250.00 ± 7.91 218.00 ± 5.48 216.00 ± 21.10 
65 257.78 ± 8.62 256.00 ± 23.61 183.33 ± 8.16aa,b 254.44 ± 8.86 218.00 ± 5.48 214.00 ± 17.89 
80 255.56 ± 9.86 256.00 ± 20.80 180.00 ± 7.07aa,b 250.00 ± 6.61 200.00 ± 6.12A 212.00 ± 17.82A 
95 261.11 ± 7.99 256.00 ± 25.88 183.33 ± 10.80aa,b 248.89 ± 7.80 208.00 ± 8.22 214.00 ± 14.83 
110 263.33 ± 9.68 258.00 ± 21.62 186.67 ± 8.16aa,b 252.22 ± 7.45 200.00 ± 6.12 216.00 ± 11.51 
125 265.56 ± 9.20 258.00 ± 23.02 180.00 ± 14.14aa,bb 245.56 ± 6.15 194.00 ± 4.47A 216.00 ± 17.89BB 
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Table 3 - Raw data values of coronary flow (CF) in ml/minute/gram heart weight obtained 914 
during 125 minutes of Langendorff perfused Control or Sunitinib (1 µM) hearts. Groups: 3 915 
month (n=9), 12 month (n=6), and 24 month (Control: n=3; Sunitinib: n=5). Data expressed 916 
at mean ± S.E.M. Two-way ANOVA statistical analysis with Tukey post hoc test: 12 month 917 
and 24 month versus 3 month control: a (p<0.05); 24 month versus 12 month control: b 918 
(p<0.05); 12 month and 24 month versus 3 month Sunitinib: A (p<0.05) and AA (p<0.01); 24 919 
month versus 12 month Sunitinib: B (p<0.05). 920 
CF Control Sunitinib 
Time 3 month 12 month 24 month 3 month 12 month 24 month 
0 7.29 ± 0.42 6.94 ± 0.22 3.81 ± 0.17a 6.10 ± 0.80 7.44 ± 0.91 5.57 ± 0.90 
5 7.68 ± 0.38 7.17 ± 0.28 3.81 ± 0.17a 6.18 ± 0.82 8.58 ± 0.79 5.47 ± 0.83 
10 7.93 ± 0.59 7.36 ± 0.42 3.98 ± 0.14a 5.91 ± 0.87 8.32 ± 0.82 5.48 ± 0.57 
15 7.67 ± 0.65 7.40 ± 0.56 3.81 ± 0.12a 5.75 ± 0.75 7.96 ± 0.67 5.09 ± 0.74 
20 7.36 ± 0.50 7.35 ± 0.39 3.73 ± 0.08a 5.85 ± 0.83 7.70 ± 0.76 5.24 ± 0.88 
25 7.21 ± 0.47 7.65 ± 0.45 3.73 ± 0.14a,b 5.87 ± 0.88 8.05 ± 0.71 5.02 ± 1.04 
30 6.79 ± 0.52 7.37 ± 0.38 3.73 ± 0.14 5.58 ± 0.85 8.12 ± 0.70 5.16 ± 0.94 
35 6.91 ± 0.53 7.55 ± 0.42 3.49 ± 0.08b 5.45 ± 0.90 8.24 ± 0.73A 5.10 ± 0.75AA 
50 6.81 ± 0.56 7.55 ± 0.59 3.41 ± 0.05b 4.84 ± 0.93 8.04 ± 0.78A 5.08 ± 0.68AA 
65 6.59 ± 0.58 6.82 ± 0.61 3.41 ± 0.05 4.51 ± 0.85 7.93 ± 0.79AA 4.68 ± 0.58AA,B 
80 6.43 ± 0.51 6.85 ± 0.70 3.41 ± 0.05 4.35 ± 0.85 7.07 ± 0.62 4.54 ± 0.82 
95 6.31 ± 0.57 6.24 ± 0.89 3.25 ± 0.09 4.06 ± 0.62 6.92 ± 0.51A 4.54 ± 0.74 
47 
 
110 6.12 ± 0.57 6.29 ± 0.93 3.25 ± 0.09 3.89 ± 0.61 6.19 ± 0.55 4.22 ± 0.84 
125 5.93 ± 0.56 5.78 ± 0.76 3.17 ± 0.06 3.89 ± 0.62 5.55 ± 0.72 3.87 ± 0.69 
 921 
 922 
 923 
